FFAR4 is targeted therapeutically in clinical trials for the treatment of metabolic disease (clinicaltrials.gov identifier: NCT03285750, NCT02444910, NCT03062592, NCT05068557). This evidence concerns the gene FFAR4 and Other metabolic disease.